Lexaria Bioscience Begins Largest Cannabinoid R&D Program in its History
Kelowna, British Columbia – March 20, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that work has commenced on…
Lexaria Bioscience comments on FDA Statement on Novel Nicotine Replacement Therapies
Kelowna, British Columbia – February 26, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, comments on the February 21, 2019…
Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria’s DehydraTECH™ Powered TurboCBD™ Capsules
Kelowna, British Columbia – February 21, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce additional significant…
Lexaria Warrant Exercises
Kelowna, British Columbia – February 15, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received funds from…
Lexaria Warrant Exercises
Kelowna, British Columbia – January 25, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received funds from…
Lexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH™ Technology for Oral Nicotine
Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement. The Altria investment will fund research on regulatory compliant, oral forms of nicotine…
Lexaria Bioscience Expands Staff, Issues Options
Kelowna, British Columbia – December 7, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces the following updates. The Company…
Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer
Kelowna, British Columbia – November 26, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has submitted a Health…
Lexaria Bioscience Launches ChrgD+
Kelowna, British Columbia – November 13, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces the launch of ChrgD+, a…
Lexaria Bioscience Announces Increased Size and Closing of Private Placement
Kelowna, British Columbia – October 31, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that due to strong demand…